121 results
DEFA14A
MLTX
MoonLake Immunotherapeutics - Ordinary Shares
24 Apr 24
Additional proxy soliciting materials
4:31pm
of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024.For3. Approval
8-K
EX-99.2
i9ub7ny7
11 Mar 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
iwuy34 ysdn8r
6 Nov 23
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
7:55am
8-K
EX-1.1
gh6z r195
29 Jun 23
Entry into a Material Definitive Agreement
4:13pm
424B5
e0k79vt4
29 Jun 23
Prospectus supplement for primary offering
4:02pm
424B5
gcavn7suion g7
26 Jun 23
Prospectus supplement for primary offering
4:23pm